Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen W Fesik

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Thescientificworldjournal|August 28, 2018
BCL-2 AND IAP Proteins As Potential Drug TargetsStephen W Fesik
Chemical Reviews|March 5, 2025
Drugging Challenging Cancer Targets Using Fragment-Based MethodsStephen W Fesik
Nature Reviews. Cancer|October 22, 2005
Promoting apoptosis as a strategy for cancer drug discoveryStephen W Fesik
Pharmacology & Therapeutics|August 31, 2014
Small molecule Mcl-1 inhibitors for the treatment of cancerJohannes Belmar, Stephen W Fesik
Protein Expression and Purification|September 11, 2004
Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptideZhihong Liu, Edward T Olejniczak, Stephen W Fesik
Journal of Clinical Medicine|January 11, 2024
WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You ThinkApril M Weissmiller, Stephen W Fesik, William P Tansey
Medchemcomm|August 16, 2018
Recent advancements in the discovery of protein-protein interaction inhibitors of replication protein AJames D Patrone, Alex G Waterson, Stephen W Fesik
Biochimica Et Biophysica Acta|March 5, 2004
Structural biology of the Bcl-2 family of proteinsAndrew M Petros, Edward T Olejniczak, Stephen W Fesik
Journal of Biomolecular NMR|September 1, 2005
1H, 13C and 15N resonance assignments of a Bcl-xL/Bad peptide complexAndrew M Petros, Stephen W Fesik, Edward T Olejniczak
Journal of Biomolecular NMR|May 21, 2013
Fragment-based drug discovery using NMR spectroscopyMary J Harner, Andreas O Frank, Stephen W Fesik
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Thescientificworldjournal|August 28, 2018
BCL-2 AND IAP Proteins As Potential Drug TargetsStephen W Fesik
Chemical Reviews|March 5, 2025
Drugging Challenging Cancer Targets Using Fragment-Based MethodsStephen W Fesik
Nature Reviews. Cancer|October 22, 2005
Promoting apoptosis as a strategy for cancer drug discoveryStephen W Fesik
Pharmacology & Therapeutics|August 31, 2014
Small molecule Mcl-1 inhibitors for the treatment of cancerJohannes Belmar, Stephen W Fesik
Protein Expression and Purification|September 11, 2004
Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptideZhihong Liu, Edward T Olejniczak, Stephen W Fesik
Journal of Clinical Medicine|January 11, 2024
WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You ThinkApril M Weissmiller, Stephen W Fesik, William P Tansey
Medchemcomm|August 16, 2018
Recent advancements in the discovery of protein-protein interaction inhibitors of replication protein AJames D Patrone, Alex G Waterson, Stephen W Fesik
Biochimica Et Biophysica Acta|March 5, 2004
Structural biology of the Bcl-2 family of proteinsAndrew M Petros, Edward T Olejniczak, Stephen W Fesik
Journal of Biomolecular NMR|September 1, 2005
1H, 13C and 15N resonance assignments of a Bcl-xL/Bad peptide complexAndrew M Petros, Stephen W Fesik, Edward T Olejniczak
Journal of Biomolecular NMR|May 21, 2013
Fragment-based drug discovery using NMR spectroscopyMary J Harner, Andreas O Frank, Stephen W Fesik
Pageof 12